Mashima, Kiyomi https://orcid.org/0000-0002-4736-3285
Kuang, Yanan
Fernandes, Stacey M.
Xu, Shidong https://orcid.org/0009-0003-6800-0939
Hanna, Benjamin
Shupe, Samantha
Mikhaleva, Mariia https://orcid.org/0000-0002-2135-2051
Santos, Roberta Azevedo
Predko, Paulina
Fardoun, Rayan
Bidgoli, Ava
Martindale, Stephen P.
Naeem, Aishath
Davids, Matthew S. https://orcid.org/0000-0003-4529-2003
Paweletz, Cloud
Brown, Jennifer R.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA258924, R01CA213442)
The Tree of Life team of the Jimmy Fund Walk is a fundraising team for cancer treatment and research.
Article History
Received: 27 September 2024
Revised: 17 March 2025
Accepted: 7 April 2025
First Online: 23 June 2025
Competing interests
: In the interest of full disclosure, we wish to declare the following potential conflicts of interest: KM, YK, SMF, SX, BH, SS, MM, RAS, PP, RF, AB, SPM, AN and CP have no relevant conflicts of interest to disclose. MSD has received institutional research funding from AbbVie, AstraZeneca, Ascentage Pharma, Genentech, MEI Pharma, Novartis, Surface Oncology, TG Therapeutics, and personal consulting income from AbbVie, Adaptive Biosciences, Ascentage Pharma, AstraZeneca, BeiGene, BMS, Eli Lilly, Genentech, Genmab, Janssen, Merck, Mingsight Pharmaceuticals, Nuvalent, ONO Pharmaceuticals, Secura Bio, TG Therapeutics, and Takeda. JRB has served as a consultant for Abbvie, Acerta/Astra-Zeneca, Alloplex Biotherapeutics, BeiGene, Bristol-Myers Squibb, EcoR1, Galapagos NV, Genentech/Roche, Grifols Worldwide Operations, Hutchmed, InnoCare Pharma Inc, iOnctura, Kite Pharma, Loxo/Lilly, Merck, Numab Therapeutics, Pfizer, Pharmacyclics; received research funding from BeiGene, Gilead, iOnctura, Loxo/Lilly, MEI Pharma, SecuraBio, and TG Therapeutics; and serves on the Data Safety Monitoring Board for Grifols Therapeutics.